Overview

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2025-01-15

Target enrollment:

Participant gender:

Summary

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Rochester

Collaborator:

Medical College of Wisconsin

Treatments:

Lisinopril